◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksE › ERF

Eurofins Scientific SE (ERF) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Diagnostics & Research · DATA UPDATED 2026-08-16

Eurofins Scientific SE (ERF) operates in the Diagnostics & Research industry and is headquartered in Luxembourg, Luxembourg with about 65,000 employees. Its market capitalization is roughly €12 billion. In the fiscal year ended 2025-12-31, ERF reported €7.3B in revenue and €475M in net income.

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide.

Interactive charts & full statements →

ERF Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue€7.3B€7.0B€6.5B€6.7B
Gross Profit€5.0B€4.7B€4.4B€4.5B
Operating Income (EBIT)€818M€726M€547M€783M
Net Income€475M€406M€310M€610M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ERF Free Cash Flow History

Cash flow2025-12-312024-12-312023-12-312022-12-312021-12-31
Dividends Paid(€108M)(€96M)(€192M)(€192M)

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ERF Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets€11.0B€10.9B€10.9B€10.1B
Total Liabilities€6.4B€5.5B€5.8B€5.2B

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ERF viewer.

Other Companies in Diagnostics & Research

← ERDAll “E” companiesERIE →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.